CTLA-4: new insights into its biological function and use in tumor immunotherapy

Enhancement of Antitumor Immunity by CTLA-4 Blockade

Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,820

Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4

Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233

CTLA-4 can function as a negative regulator of T cell activation

Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222

Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation

Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206

B7/CD28 Costimulation Is Essential for the Homeostasis of the CD4+CD25+ Immunoregulatory T Cells that Control Autoimmune Diabetes

Salomon, B. L., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A. H., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,058

The B7–CD28 superfamily

Sharpe, A. H., & Freeman, G. J. (2002) · Nature reviews. Immunology · doi:10.1038/nri727 · Cited by 1,759

A New Frontier of Neoadjuvant Immunotherapy for Hepatocellular Carcinoma

任, 秋. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.133628

Data from Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals

Mitsui, J., Nishikawa, H., Muraoka, D., Wang, L., Noguchi, T., Sato, E., Kondo, S., Allison, J. P., Sakaguchi, S., Old, L. J., et al. (2023) · doi:10.1158/1078-0432.c.6519084.v1

Data from CCL2 Blockade Augments Cancer Immunotherapy

Fridlender, Z. G., Buchlis, G., Kapoor, V., Cheng, G., Sun, J., Singhal, S. K., Crisanti, M. C., Wang, L. S., Heitjan, D. F., Snyder, L. A., et al. (2023) · doi:10.1158/0008-5472.c.6500100.v1

Data from T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival

Boorjian, S. A., Sheinin, Y. M., Crispen, P. L., Farmer, S. A., Lohse, C. M., Kuntz, S. M., Leibovich, B. C., Kwon, E. D., & Frank, I. (2023) · doi:10.1158/1078-0432.c.6517137

Data from Invariant Natural Killer T Cells Regulate Breast Cancer Response to Radiation and CTLA-4 Blockade

Pilones, K. A., Kawashima, N., Yang, A. M., Babb, J. S., Formenti, S. C., & Demaria, S. (2023) · doi:10.1158/1078-0432.c.6517717

Data from Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals

Mitsui, J., Nishikawa, H., Muraoka, D., Wang, L., Noguchi, T., Sato, E., Kondo, S., Allison, J. P., Sakaguchi, S., Old, L. J., et al. (2023) · doi:10.1158/1078-0432.c.6519084

Data from Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer

Vathiotis, I. A., Moutafi, M. K., Divakar, P., Aung, T. N., Tao, Q., Fernandez, A. I., Yaghoobi, V., El-Abed, S., Wang, Y., Guillaume, S., et al. (2023) · doi:10.1158/1078-0432.c.6530457

Data from T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival

Boorjian, S. A., Sheinin, Y. M., Crispen, P. L., Farmer, S. A., Lohse, C. M., Kuntz, S. M., Leibovich, B. C., Kwon, E. D., & Frank, I. (2023) · doi:10.1158/1078-0432.c.6517137.v1

Data from Enhancing the Generation of Eomeshi CD8+ T Cells Augments the Efficacy of OX40- and CTLA-4–Targeted Immunotherapy

Emerson, D. A., Rolig, A. S., & Redmond, W. L. (2023) · doi:10.1158/2326-6066.c.6550189

Data from Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity

Redmond, W. L., Linch, S. N., & Kasiewicz, M. J. (2023) · doi:10.1158/2326-6066.c.6548227.v1

Comprehensive Analysis of the Expression of IGFBPs and its Correlation with Prognosis and Immune in Endometrial CancerPreprint

Jin, Y., Qi, M., Cai, M., Si, L., Fu, H., Liu, Y., & Guo, R. (2023) · Research Square · doi:10.21203/rs.3.rs-3479713/v1

References

(2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21798-2.16001-4

Cancer Immunotherapies Targeting Cancer Stem Cells: Concepts, Applications, and Advances

Farhangnia, P., Shokri, M.-R., Akbarpour, M., & Delbandi, A. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_401

Immunotherapy to CD5, a T-cell antigen having roles from development to peripheral function: Future prospective and challenges

Choubey, R. B., Sweta, Vibha, Sharma, A., & Rai, A. K. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.10.007

The Immunoradiotherapy in Nasopharyngeal Carcinoma

Miao, J., Xiang, C., & Liu, C. (2025) · Springer eBooks · doi:10.1007/978-981-96-3659-4_6

Could your gut microbes hinder your cancer treatment? A new first-in-human trial investigates

Davar, D. (2018) · doi:10.64628/aai.v65vuesgc

Nivolumab plus Ipilimumab in Relapsed Locally Advanced NSCLC Post-Durvalumab Consolidation: A Retrospective Efficacy and Safety Analysis

Flores, M., Quispe, L. E. M., & Torres, E. (2025) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/hsbhy4z8cq

Combination BRAF-Directed Therapy and Immunotherapy

Cooper, Z. A., Ahmed, Z., & Wargo, J. A. (2014) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4939-2143-0_8

Cutaneous Melanoma: Therapeutic Approaches for Metastatic Disease

Tarhini, A. A., & Kirkwood, J. M. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511976117.031

T-Zelltoleranz und Autoimmunität

Kamradt, T., Hansen, G., Bechmann, I., & Burmester, G. (2003) · Der Internist · doi:10.1007/s00108-002-0772-9

Effects of linear energy transfer and hypoxia on radiation-induced immunogenicity through STING

MILES, D. A. (2020) · Purdue e-Pubs (Purdue University System) · doi:10.25394/pgs.12200867

Additional file 1 of Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W.-J., Liu, Z., & Cheng, Q. (2021) · Figshare · doi:10.6084/m9.figshare.14737077

Additional file 1 of An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy

Sibilio, P., Belardinilli, F., Licursi, V., Paci, P., & Giannini, G. (2022) · Figshare · doi:10.6084/m9.figshare.19736418

Influence de la Transition Epithélio-Mésenchymateuse sur la réponse T cytotoxique anti-tumorale

Akalay, I. (2013) · theses.fr (ABES) · doi:10.70675/cb446c70z6112z416ez9557z9831373b9e40

Peptides d'élastine et modulation de la réponse T helper au cours de la Broncho-Pneumopathie Chronique Obstructive (BPCO)

Meghraoui, A. (2015) · theses.fr (ABES) · doi:10.70675/ce13179bz3d1dz4f81z97cdz72f2ffc7885f

Immunothérapie du cancer par administration d’anticorps monoclonaux anti-HVEM ou anti-ICOS chez la souris humanisée : potentiel thérapeutique et effets immunologiques

Brunel, S. (2017) · theses.fr (ABES) · doi:10.70675/c013f943z4c05z42b3z822ezecde2f929a63

PHU RINNOPARI - Orientation de la réponse immune Thelper et rôle des peptides d’élastine au cours du remodelage des voies aériennes associé à la BPCO

Lemaire, F. (2018) · theses.fr (ABES) · doi:10.70675/31e78c33z4b63z41aez8b07z4ce8a98b32bf

Rôle chromatinien de SUMO dans l’immunité innée et ses implications dans l’immunothérapie des cancers

Morel, V. (2021) · theses.fr (ABES) · doi:10.70675/31e506dazce13z4d4cz8c40z9823077c170b

Populations lymphocytaires circulantes exprimant PD-1 au cours des cancers bronchiques avancés, valeur prédictive de réponse aux inhibiteurs de PD-1/PD-L1

Duchemann, B. (2021) · theses.fr (ABES) · doi:10.70675/fdb3aa05z2fa2z43b9za219z81ff51de1953

Latest Approaches in Cancer Therapy and Remaining Gaps

Eyüpoğlu, H. Ö., Cagsin, H., & Serakıncı, N. (2026) · OBM Genetics · doi:10.21926/obm.genet.2602339

Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies

Ge, Q., Yu, L., Lu, J., Anwaier, A., Xiao, X., Chen, Y., Ye, D., Zhang, H., Xu, W., & Dai, W. (2026) · MedComm · doi:10.1002/mco2.70771

Harnessing the abscopal effect: mechanistic insights and therapeutic strategies for systemic cancer immunotherapy

Cao, L., Tong, S., & Jiang, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1871187

Destabilization of intratumor Tregs by CTLA-4 engagement confers anti-CTLA-4-driven immunotherapyPreprint

Liu, N., Xu, J., Ku, W. L., Chen, W., Cao, Y., Kazmi, R., Jin, W., Gauthier, T., Luo, S., Shen, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.28.741328

Comparing Survival Outcomes of Monotherapy and Combination Immunotherapy Across Different Cancer Types using cBioPortal Data

Suri, A. (2026) · American journal of student research. · doi:10.70251/hyjr2348.4512331240

BindingDB Entry 50018144: Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction.

BindingDB (2024) · UC San Diego · doi:10.7270/q2p55spx

Overcoming Immune Suppression: Therapeutic Strategies Targeting T-Cell Function in Cancer

Weber, J. S. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8056-4_16

E3 ubiquitin ligases and immune tolerance: Targeting the immune synapse from within?

Puga, I., & Macián, F. (2007) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8296-4_9

Costimulatory Molecules in T CeII Activation and Transplantation

Arch, R. H., & Green, M. J. (2004) · Springer eBooks · doi:10.1007/978-1-4419-8999-4_16

Gene-Modified Tumor-Cell Vaccines

Emens, L. A., & Jaffee, E. M. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-680-5_18

DNA Vaccines for Cancer Immunotherapy

Kwak, H., & Kaufman, H. L. (2006) · Humana Press eBooks · doi:10.1385/1-59745-011-1:087

CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor Immunotherapy

Chambers, C. A., Kuhns, M. S., Egen, J. G., & Allison, J. P. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.565 · Cited by 1,000

Mechanisms of negative costimulation by CTLA-4 and its manipulation in tumor immunotherapy in mice and man

Allison, J. P. (2003) · Cancer immunity

The role of CTLA‐4 in the regulation of T cell immune responses

McCoy, K. D., & Gros, G. S. L. (1999) · Immunology and Cell Biology · doi:10.1046/j.1440-1711.1999.00795.x · Cited by 255

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy

Zhao, Y., Yang, W., Huang, Y., Cui, R., Li, X., & Li, B. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000490025 · Cited by 182

CTLA-4: a moving target in immunotherapy

Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233